Follow
italo poggesi
italo poggesi
Janssen R&D
Verified email at its.jnj.com
Title
Cited by
Cited by
Year
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni, P Magni, C Cammia, G De Nicolao, V Croci, E Pesenti, ...
Cancer research 64 (3), 1094-1101, 2004
5742004
Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors
R Bahleda, A Italiano, C Hierro, A Mita, A Cervantes, N Chan, M Awad, ...
Clinical cancer research 25 (16), 4888-4897, 2019
2112019
Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor
P Dostert, MS Benedetti, I Poggesi
European Neuropsychopharmacology 7 (1), S23-S35, 1997
1781997
Computational models for identifying potential P-glycoprotein substrates and inhibitors
P Crivori, B Reinach, D Pezzetta, I Poggesi
Molecular pharmaceutics 3 (1), 33-44, 2006
1492006
Physiologically based pharmacokinetics (PBPK)
P Espiť, D Tytgat, ML Sargentini-Maier, I Poggesi, JB Watelet
Drug metabolism reviews 41 (3), 391-407, 2009
1452009
Drug metabolism and pharmacokinetics
MS Benedetti, R Whomsley, I Poggesi, W Cawello, FX Mathy, ML Delporte, ...
Drug metabolism reviews 41 (3), 344-390, 2009
1332009
Predicting the active doses in humans from animal studies: a novel approach in oncology
M Rocchetti, M Simeoni, E Pesenti, G De Nicolao, I Poggesi
European journal of cancer 43 (12), 1862-1868, 2007
1112007
A mathematical model to study the effects of drugs administration on tumor growth dynamics
P Magni, M Simeoni, I Poggesi, M Rocchetti, G De Nicolao
Mathematical biosciences 200 (2), 127-151, 2006
1082006
Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs
P Crivori, I Poggesi
European journal of medicinal chemistry 41 (7), 795-808, 2006
972006
Child–Pugh Classification: Time to Abandon?
B Kok, JG Abraldes
Seminars in liver disease 39 (01), 096-103, 2019
852019
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
E Marostica, J Sukbuntherng, D Loury, J De Jong, XW De Trixhe, ...
Cancer chemotherapy and pharmacology 75, 111-121, 2015
842015
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
M Menichincheri, A Bargiotti, J Berthelsen, JA Bertrand, R Bossi, ...
Journal of medicinal chemistry 52 (2), 293-307, 2009
842009
Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding
DMF Edwards, C Pellizzoni, HP Breuel, A Berardi, MG Castelli, E Frigerio, ...
Biopharmaceutics & drug disposition 16 (6), 443-460, 1995
791995
Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
XS Xu, CJ Ryan, K Stuyckens, MR Smith, F Saad, TW Griffin, YC Park, ...
Clinical Cancer Research 21 (14), 3170-3177, 2015
722015
Physiologically‐based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective
T Heimbach, Y Chen, J Chen, V Dixit, N Parrott, SA Peters, I Poggesi, ...
Clinical Pharmacology & Therapeutics 110 (2), 297-310, 2021
682021
Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics
JC Fleishaker, M Mucci, C Pellizzoni, I Poggesi
Biopharmaceutics & drug disposition 20 (1), 53-57, 1999
661999
Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates
P Crivori, I Zamora, B Speed, C Orrenius, I Poggesi
Journal of computer-aided molecular design 18, 155-166, 2004
652004
Low environmental radiation background impairs biological defence of the yeast Saccharomyces cerevisiae to chemical radiomimetic agents
L Satta, G Augusti-Tocco, R Ceccarelli, A Esposito, M Fiore, P Paggi, ...
Mutation Research Letters 347 (3-4), 129-133, 1995
611995
Modeling of human tumor xenografts and dose rationale in oncology
M Simeoni, G De Nicolao, P Magni, M Rocchetti, I Poggesi
Drug Discovery Today: Technologies 10 (3), e365-e372, 2013
522013
Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development
A Bernard, H Kimko, D Mital, I Poggesi
Expert opinion on drug metabolism & toxicology 8 (9), 1057-1069, 2012
502012
The system can't perform the operation now. Try again later.
Articles 1–20